Propanc Biopharma Inc (NASDAQ:PPCB – Get Free Report) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 19,745 shares, a decline of 60.9% from the October 15th total of 50,470 shares. Based on an average daily trading volume, of 57,444 shares, the short-interest ratio is presently 0.3 days. Currently, 4.7% of the shares of the company are sold short.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.
Get Our Latest Analysis on Propanc Biopharma
Propanc Biopharma Stock Performance
NASDAQ PPCB traded down $0.05 during trading hours on Monday, hitting $1.89. The company had a trading volume of 8,490 shares, compared to its average volume of 170,750. Propanc Biopharma has a 52 week low of $1.63 and a 52 week high of $315.00. The firm has a 50 day simple moving average of $4.57 and a 200 day simple moving average of $20.32. The firm has a market capitalization of $1.19 million, a price-to-earnings ratio of -0.01 and a beta of 3.55.
Propanc Biopharma (NASDAQ:PPCB – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($12.22) earnings per share for the quarter.
About Propanc Biopharma
Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.
See Also
- Five stocks we like better than Propanc Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
